Home > Newsletters > Executive Briefing Series (formerly The Food & Drug Letter) > Nanomedicine Presents Unique Challenges to IRBs
Executive Briefing Series (formerly The Food & Drug Letter)
Dec. 16, 2011
Nanomedicine Presents Unique Challenges to IRBs
Nanomedicine is an exciting new field that offers great promise, but much about this cutting-edge technology is unknown, which argues for a precautionary approach by institutional review boards (IRB) and researchers to protect all parties involved in nanomedicine trials, a National Institutes of Health- (NIH) funded panel says.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.